A Randomized Clinical Trial to Study the Effects of MK0752 Versus Placebo on Biomarkers in Healthy Young Adult Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2015
At a glance
- Drugs MK 0752 (Primary)
- Indications Alzheimer's disease; Cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors Merck & Co
- 18 Apr 2010 Results have been reported in an abstract presented at the American Association for Cancer Research meetiing in April 2010 (AACR 2010)
- 23 Jul 2009 Actual end date changed from Apr 2009 to May 2009 as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.